Long-Acting Injectable Antipsychotics in the Era of COVID-19


COVID-19 has made treating patients who receive long-acting injectables complicated. The Chief Medical Officer of Houston Behavioral Healthcare Hospital offers suggestions on how best to proceed.

The training wheels on telepsychiatry have been yanked off. Where it was once an exception, telepsychiatry is the new norm. But how does this impact the patients who need more intense care?

Frank Chen, MD, explains.

Dr Chen is Chief Medical Officer at Houston Behavioral Healthcare Hospital.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2023 MJH Life Sciences

All rights reserved.